188 related articles for article (PubMed ID: 32753387)
1. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
3. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
4. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
Bellon M; Lu L; Nicot C
Blood; 2016 May; 127(20):2439-50. PubMed ID: 26813676
[TBL] [Abstract][Full Text] [Related]
8. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
9. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
[TBL] [Abstract][Full Text] [Related]
10. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
12. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
13. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
14. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
16. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
Weirauch U; Beckmann N; Thomas M; Grünweller A; Huber K; Bracher F; Hartmann RK; Aigner A
Neoplasia; 2013 Jul; 15(7):783-94. PubMed ID: 23814490
[TBL] [Abstract][Full Text] [Related]
17. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
[TBL] [Abstract][Full Text] [Related]
18. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
20. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
